Source: Annual Congress 2009 - Complications of respiratory infections: impact of comorbidities and infections caused by Aspergillus
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
B. Philippe, J. Cadranel, C. Hennequin, A. Bergeron, E. Bergot, P. Chanez, V. Cottin, T. Jeanfaivre, C. Godet, M. Pineau, P. Germaud (Suresnes, Paris, Caen, Montpellier, Lyon, Angers, Poitiers, Nantes, France). Voriconazole (VORI) for proven chronic pulmonary aspergillosis (CPA): a prospective multicenter trial. Eur Respir J 2009; 34: Suppl. 53, 2458

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of moxifloxacin for treatment of bronchial colonisation in COPD patients: a randomised, double-blind, placebo-controlled study Source: Annual Congress 2007 - Treatment and care of COPD Year: 2007 RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021 Open-label, randomized, comparative trial of the efficacy of levofloxacin versus clarithromycin SR therapy in complicated infectious exacerbation of COPD Source: Eur Respir J 2007; 30: Suppl. 51, 674s Year: 2007 Pulmonary vasodilator therapy in severe COPD: a double-blind, placebo-controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 525s Year: 2007 A randomized, placebo-controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease(COPD) Source: Annual Congress 2010 - New aspects of treatment of lower respiratory tract infections Year: 2010 Azithromycin and Hydroxychloroquine in hospitalized patients with confirmed SARS-CoV-2 infection - a randomized placebo-controlled trial (ProPAC-COVID Trial) Source: Virtual Congress 2021 – COVID - 19 treatments Year: 2021 A prospective randomised double-blind placebo controlled trial of venlafaxine in patients with stable chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 32s Year: 2006 Caspofungin pulses for CPA (chronic pulmonary aspergillosis): A retrospective study Source: International Congress 2016 – Severe respiratory infections in the intensive care unit and pleural and fungal infections Year: 2016 Azithromycin for the treatment of cough in idiopathic pulmonary fibrosis: A randomized controlled cross-over pilot trial. Source: Virtual Congress 2020 – Chronic cough: only symptom or disease? Year: 2020 An open label randomized controlled trial comparing nebulized amphotericin B with oral itraconazole in patients with pulmonary aspergilloma Source: Virtual Congress 2020 – Aspergillosis and chronic lung infections Year: 2020 LATE-BREAKING ABSTRACT: COPD-associated severe pulmonary hypertension (COPDPH): results of a 16-weeks prospective multicenter, double-blind, placebo-controlled randomized clinical trial (RCT) [SPHERIC-1 (http://clinicaltrials.gov/ct2/show/NCT01441934)] investigating the effect of sildenafil citrate (Sld) on pulmonary vascular resistance (PVR) and PaO2. Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013 Preliminary results of a prospective, multicentric randomized study comparing Interferon Gamma-1b (IFN-γ) and colchicine in the treatment of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2003 - Interstitial lung diseases Year: 2003 Late Breaking Abstract - First-time assessment of efficacy of candidate vaccine to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD): multicentre, randomised, controlled, observer-blind phase 2b trial Source: Virtual Congress 2021 – ALERT: COPD Year: 2021 Multicenter, randomized, double-blind, placebo-controlled study (ORBIT 1) to evaluate the efficacy, safety, and tolerability of once daily ciprofloxacin for inhalation in the management of pseudomonas aeruginosa infections in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis Year: 2011 Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Source: Eur Respir J 2002; 20: 245 Year: 2002 A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis Source: Eur Respir J, 53 (3) 1801992; 10.1183/13993003.01992-2018 Year: 2019 Inhaled rhGM-CSF (molgramostim) in the first randomised, double-blind, placebo-controlled, international trial in patients with autoimmune alveolar proteinosis (aPAP) Source: International Congress 2016 – Orphan diseases I Year: 2016 First data about the efficacy of moxifloxacin in the treatment of pulmonary tuberculosis – a prospective, randomised study versus INH Source: Annual Congress 2003 - Management of tuberculosis and tubercular infection - old and new considerations Year: 2003 Effectiveness of azithromycin (AZ) in patients with community-acquired pneumonia (CAP): an evidenced-based meta-analysis of randomized controlled trials (RCTs) Source: Eur Respir J 2001; 18: Suppl. 33, 137s Year: 2001 A clinical and outcomes assessment of the management of community-acquired pneumonia (CAP): a multinational, prospective, double-blind comparison of moxifloxacin to standard first-line oral monotherapy or combination regimen Source: Eur Respir J 2001; 18: Suppl. 33, 189s Year: 2001